Moderna is expected to report Q2 2026 revenue of $103.1 million and an EPS loss of $1.97, with its current share price of $55.63 trading above the average analyst target of $49.37.
Investors are laser-focused on the commercial traction of mRESVIA, Moderna’s newly launched RSV vaccine, alongside updates on its late-stage pipeline including anticipated Phase III melanoma data.
This quarter is typically seasonally weak for respiratory vaccine sales, shifting the spotlight to management's full-year 2026 guidance and cash burn rate. Despite the revenue contraction compared to last year, the company has beaten earnings estimates for seven consecutive quarters, maintaining confidence in its long-term platform diversification.